budesonide + formoterol + umeclidinium

This is a fixed-dose **combination drug composed of budesonide, formoterol, and umeclidinium**. Budesonide is an inhaled corticosteroid that reduces airway inflammation; formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle; and umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine action on airway smooth muscle, leading to bronchodilation. The triple combination is designed to treat **chronic obstructive pulmonary disease (COPD)** and potentially severe asthma, aiming to provide both anti-inflammatory effects and dual bronchodilation. While there are approved triple therapies using similar components (e.g., fluticasone/umeclidinium/vilanterol or budesonide/glycopyrrolate/formoterol), an approved fixed-dose combination of specifically budesonide + formoterol + umeclidinium does not appear to be currently marketed or approved. Its mechanism draws from established use of these pharmacologic classes in combination for COPD management.